1050 Results

People

  1. Giralt
    Giralt
  2. Perales
    Perales
  3. Shah
    Shah
  4. Scordo
    Scordo
  5. Landau
    Landau
  6. Jakubowski
    Jakubowski
  7. Devlin
    Devlin
  8. Papadopoulos
    Papadopoulos
  9. Dahi
    Dahi
  10. Hassoun
    Hassoun

Groups

  1. Bone Marrow Transplant (1050)
  2. Center for Hematologic Malignancies (1050)
  3. Department of Medicine (1050)
  4. Hematologic Malignancies, Division of (1050)
  5. Survivorship Research (684)
  6. CTCR Scholars (539)
  7. Epidemiology and Biostatistics (477)
  8. Biostatistics Service (465)
  9. MSK Grad Students (393)
  10. Master of Science in Clinical and Translational Cancer Research (379)
  1. "Sergio Giralt"
Formats
  1. Meeting Abstract (632)
  2. Journal Article (371)
  3. Research Letter (17)
  4. Review (15)
  5. Guidelines (5)
  6. Editorial (4)
  7. Book Section (3)
  8. Correspondence (3)
Groups
  1. Bone Marrow Transplant (1050)
  2. Center for Hematologic Malignancies (1050)
  3. Department of Medicine (1050)
  4. Hematologic Malignancies, Division of (1050)
  5. Survivorship Research (684)
  6. CTCR Scholars (539)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (421)
  3. Sean Devlin (372)
  4. Gunjan Shah (297)
  5. Michael Scordo (266)
  6. Heather Landau (253)

More People

Years
  1. 2025 (9)
  2. 2024 (55)
  3. 2023 (104)
  4. 2022 (77)
  5. 2021 (66)
  6. 2020 (91)

More Years

Publications
  1. Blood (304)
  2. Biology of Blood and Marrow Transplantation (275)
  3. Bone Marrow Transplantation (80)
  4. Clinical Lymphoma, Myeloma and Leukemia (60)
  5. Journal of Clinical Oncology (40)
  6. Transplantation and Cellular Therapy (36)

More Publications

Publishers
  1. Elsevier Inc. (384)
  2. American Society of Hematology (336)
  3. Nature Publishing Group (108)
  4. American Society of Clinical Oncology (42)
  5. Taylor & Francis Group (35)
  6. Ferrata Storti Foundation (13)

More Publishers

Results (1050)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of B cell immune reconstituion on non-relapse mortality in T cell depleted allogeneic hematopoietic cell transplantation
    Meeting Abstract

    Lucas, A. T.; Scordo, M.; Lakkaraja, M.; White, C.; Mauguen, A.; Shaffer, B.; Jakubowski, A.; Cho, C.; Gyurkocza, B.; Papadopoulos, E.; more...
    Cytotherapy (2025)

    Fulltext@MSK | Save
  • An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
    Journal Article

    Raj, S. S.; Fei, T.; Fried, S.; Ip, A.; Fein, J. A.; Leslie, L. A.; Alarcon Tomas, A.; Leithner, D.; Peled, J. U.; Corona, M.; more...
    Nature Medicine (2025)

    Fulltext@MSK | Save
  • Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
    Journal Article

    Shahid, S.; Prockop, S. E.; Flynn, G. C.; Mauguen, A.; White, C. O.; Bieler, J.; McAvoy, D.; Hosszu, K.; Cancio, M. I.; Jakubowski, A. A.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • A Shared Care Model between community and transplant centers facilitates access to allogeneic and autologous transplantation
    Journal Article

    Fein, J. A.; McAuliffe, A.; Fischer, K.; Brady, O.; Devlin, S. M.; Willumsen, S.; Ozcan, G.; Montanaro, P.; Pristyazhnyuk, Y.; DiGiuseppe, J.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
    Journal Article

    Boardman, A. P.; Gutgarts, V.; Flynn, J. R.; Devlin, S. M.; Goldman, A.; Tomas, A. A.; Fein, J. A.; Slingerland, J. B.; Parascondola, A.; Lin, R. J.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: Results from a large retrospective cohort
    Journal Article

    Melica, G.; Luna de Abia, A.; Shah, G. L.; Devlin, S.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Lin, R. J.; Palomba, M. L.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-cell (CART) therapies in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Maura, F.; Freeman, C. L.; Lee, H.; Maclachlan, K. H.; Durante, M.; Ziccheddu, B.; Menges, M.; Diamond, B.; Papadimitriou, M.; Silva, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save